US Congress confirms new drug patent listing law
22-12-2020
FDA to alter biosimilar ‘suffix’ policy
08-03-2019
FDA releases plan to boost biosimilars development
13-12-2018
Jarretera / Shutterstock.com
The Food and Drug Administration (FDA) has issued final guidance on the pathway for ‘interchangeable’ biosimilar products, in a bid to promote competition in the biologics market.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Food and Drug Administration, FDA, Ned Sharpless, biologics, biosimilar, biosimilar action plan, competition
